ADAGRASIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 388 adverse event reports in the FDA FAERS database where ADAGRASIB was used for Lung neoplasm malignant.
Most Reported Side Effects for ADAGRASIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 272 | 30.3% | 258 | 21 |
| Diarrhoea | 113 | 12.6% | 9 | 46 |
| Hospitalisation | 108 | 12.0% | 7 | 108 |
| Nausea | 87 | 9.7% | 13 | 47 |
| Vomiting | 79 | 8.8% | 11 | 44 |
| Off label use | 70 | 7.8% | 12 | 27 |
| Asthenia | 61 | 6.8% | 10 | 39 |
| Fatigue | 51 | 5.7% | 4 | 21 |
| Decreased appetite | 43 | 4.8% | 4 | 20 |
| Dehydration | 35 | 3.9% | 3 | 25 |
| Dyspnoea | 32 | 3.6% | 7 | 18 |
| Dizziness | 27 | 3.0% | 3 | 16 |
| Acute kidney injury | 26 | 2.9% | 6 | 19 |
| Weight decreased | 24 | 2.7% | 7 | 12 |
| General physical health deterioration | 19 | 2.1% | 7 | 12 |
Other Indications for ADAGRASIB
Product used for unknown indication (189)
Non-small cell lung cancer (92)
Lung adenocarcinoma (42)
Colon cancer (41)
Lung adenocarcinoma stage iv (20)
Non-small cell lung cancer metastatic (15)
Bronchial carcinoma (13)
Colorectal cancer (11)
Colorectal cancer metastatic (9)
Non-small cell lung cancer stage iv (9)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)